
    
      This is an open-label study that will be conducted at three sites in China to characterize
      the PK/PD profile, safety and tolerability of Recombinant Human Serum Albumin/interferon
      alpha2b Fusion Protein in HBV subjects. Subjects will receive a single dose of Recombinant
      Human Serum Albumin/interferon alpha2b Fusion Protein or active comparator Pegasys at Day 0.
      A multipule-dose administration in HBV subjects will last 12 weeks after four weeks washout
      period.
    
  